HCPCS Code C9097

Inj, faricimab-svoa, 0.1 mg
Code effective Oct 01, 2022

HCPCS Section
Temporary Codes for Use with Outpatient Prospective Payment System

C9097 is a valid 2026 HCPCS code meaning Inj, faricimab-svoa, 0.1 mg or (Inj, faricimab-svoa, 0.1 mg) for short. HCPCS C9097 has been effective since 10/01/2022 and applies to Medical care.

HCPCS Code Details - C9097

HCPCS Level II Code
Section C - Temporary Codes for Use with Outpatient Prospective Payment System
HCPCS Code C9097
Description

Long description:
Inj, faricimab-svoa, 0.1 mg

Short description:
Inj, faricimab-svoa, 0.1 mg

HCPCS Pricing indicator 53 - Statute
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Coverage code C - Carrier judgment
BETOS2 code O1E - Other drugs
HCPCS Action code N - No maintenance for this code
Type of service 1 - Medical care
Effective date Effective Oct 01, 2022
Date added Added Jul 01, 2022
Termination date Sep 30, 2022

See also

  • HCPCS C9096 · Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram

  • HCPCS C9098 · Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.